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Abstract—The dapE-encoded N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) is a critical bacterial enzyme for the 
construction of the bacterial cell wall.  A screen biased toward compounds containing zinc-binding groups (ZBG’s) including thiols, 
carboxylic acids, boronic acids, phosphonates and hydroxamates has delivered a number of micromolar inhibitors of DapE from H. 
influenzae, including the low micromolar inhibitor L-captopril (IC50 = 3.3 µM, Ki = 1.8 µM).  In vitro antimicrobial activity was 
demonstrated for L-captopril against E. coli.
Bacterial infections are a significant and growing 
medical problem in both the United States and around 
the world.1  The CDC recently reported that there are 
now several strains of Staphylococcus aureus that are 
resistant to all known antibiotics including 
vancomycin.2  These cases underscore the fact that 
limited numbers of drugs are available to prevent a 
simple Staph infections from becoming deadly.3  At 
least four other strains of common bacterial species 
capable of causing life-threatening illnesses 
(Enterococcus faecalis, Mycobacterium tuberculosis, 
Escherichia coli O157:H7, and Pseudomonas 
aeruginosa) are already resistant to nearly all drugs in 
clinicians arsenal comprised of more than 100 drugs.4, 5  
Thus, the search for new antibiotics that target enzymes 
in unexplored bacterial biosynthetic pathways is 
critically important, as confirmed in Supuran’s excellent 
review of bacterial protease inhibitors.6 
 
The dapE-encoded N-succinyl-L,L-diaminopimelic acid 
desuccinylase (DapE) enzyme is a member of the meso-
diaminopimelate (mDAP)/lysine biosynthetic pathway.7  
The amino acids mDAP and/or lysine are essential 
components of the peptidoglycan cell wall for Gram-
negative and most Gram-positive bacteria, providing a 
link between polysaccharide strands.7  Therefore, 
enzymes involved in the mDAP/lysine biosynthetic 
pathway, including DapE, are potential antibiotic 
targets.   
DapE's are small, dimeric enzymes (41.6 kDa/subunit) 
that require two Zn(II) ions per mole of polypeptide for 
full enzymatic activity.8,9 On the basis of sequence 
alignments with other aminopeptidases10 and several 
DapE gene sequences, all of the residues that function 
as ligands in the dinuclear active site of those enzymes 
are strictly conserved in DapE from Haemophilus 
influenzae.  Studies on the E134A- and E134D- altered 
DapE revealed that E134 acts as the general acid/base in 
the hydrolysis of the substrate and is absolutely required 
for catalytic activity.11  Investigations on H67A- and 
H349A-altered enzymes together with construction of a 
three-dimensional homology structure of DapE from H. 
influenzae (generated using the X-ray crystal structure 
of the Apo-DapE from Neisseria meningitidis as a 
template with superposition on the structure of the 
aminopeptidase from Aeromonas proteolytica (AAP)) 
confirmed the identification of active-site histidine zinc 
ligands.12  Based on this homology model, the active 
site of DapE contains two Zn(II) ions at a distance of 
~3.30 Å (Figure 1).   
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Figure 1. Proposed active site of DapE enzymes. 
 
Each of the Zn(II) ions adopts a distorted tetrahedral  
geometry and is coordinated by one imidazole group 
(H67 for Zn1 and H349 for Zn2) and one carboxylate 
group (E163 for Zn1 and E135 for Zn2).  Both Zn(II) 
ions are bridged by an additional carboxylate groups (D 
100) on one side and water/hydroxide on the opposite 
side, forming a (µ-aquo)(µ-carboxylato)dizinc(II) core 
with one terminal carboxylate and one histidine residue 
at each metal site.   
 
In order to identify appropriate lead molecules for the 
inhibition of DapE, we have screened13 over thirty 
molecules representing various structural classes and 
containing different zinc-binding groups (ZBG’s) using 
N-succinyl L,L-diaminopimelic acid (L,L-SDAP) as the 
substrate.14  These ZBG’s include thiols, hydroxamates, 
carboxylic acids, boronic acids, and phosphates, and 
this fruitful initial screen has led to the identification of 
a number of low micromolar inhibitors (Table 1).  We 
biased our initial screen to include bifunctional 
molecules that contained, in addition to the ZBG, a 
carboxylate moiety that could interact with the 
positively-charged lysine and/or arginine side chains 
that purportedly reside near the active site. Table 1 
shows carboxylic acid-containing thiols that were found 
to inhibit DapE fairly potently. Even delta-
mercaptobutyric acid has an IC50 of 43 µM versus 
DapE, and meta-mercaptobenzoic acid has a measured 
IC50 of 34 µM.  L-penicillamine gave an IC50 of 13.7 
µM, and a measured Ki of 4.6 µM.  DapE is 
stereoselective with respect to recognition of inhibitors, 
as D-penicillamine gave an IC50 of 50 µM.  Given the 
success with these carboxylic acid-containing thiols, we 
turned our attention to captopril, which contains the 
requisite ZBG and carboxylate functionalities.  L-
Captopril exhibited an IC50 of 3.3 µM and a measured 
Ki of 1.8 µM (competitive).  Again, the binding is 
stereoselective, as D-captopril15 was an order of 
magnitude less potent, with an IC50 of 42.0 µM.   
 
Table 2 shows boronic acid derivatives that were tested 
as inhibitors of DapE.  Phenylboronic acid itself was 
encouraging with an IC50 of 107 µM and a measured Ki 
of 56.9 µM (competitive).  Incorporation of a carboxylic 
acid along with the boronic acid was not productive, as 
both 4-carboxyphenylboronic acid and 3- 
carboxyphenylboronic acid did not inhibit DapE.  It is 
hypothesized that geometric constraints may have 
 
Table 1. Thiols tested as inhibitors of DapE 
Compound Structure IC50 (µM) 
delta-mercapto-
butyric acid 
 
43±4 
3-mercapto-
benzoic acid 
 
34 
L- penicillamine 
 
13.7 
Ki =4.6±0.6 µM 
(competitive) 
D-penicillamine 
 
50 
 
L-Captopril 
 
 
3.3 
Ki 
=1.82±0.09µM 
(competitive) 
D-Captopril 
 
 
42.0±2.5 
 
aValues are means of three experiments, standard deviation is given in 
parentheses. 
 
precluded a productive Coulombic interaction of the 
carboxylate with positively charged residues in the 
active site.  Butylboronic acid was a weak inhibitor of 
DapE (IC50 ~10 mM).  2-Thiopheneboronic acid was 
comparable to phenylboronic acid, with an IC50 of 92 
µM and a measured Ki of 67 µM, but the inhibitor was 
noncompetitive.  Surprisingly, 1-butaneboronic is only a 
very weak inhibitor of DapE (IC50 ~ 10,000 µM) even 
though it is a potent inhibitor of AAP (Ki = 10 µM).16, 17 
 
Table 2. Boronic acid tested as inhibitors of DapE 
Compound Structure IC50 (µM) 
phenylboronic acid 
 
107/154 µM 
Ki=56.9±3.6 µM 
(competitive) 
4-carboxyphenyl-
boronic acid 
 
>10,000 
3-carboxyphenyl-
boronic acid 
 
>10,000 
butylboronic acid 
 
~10,000 uM 
2-thiopheneboronic 
acid 
 
92 µM 
Ki=67±3.8 µM 
(non-competitive) 
aValues are means of three experiments, standard deviation is given in 
parentheses.   
 
Table 3 shows several other compounds that were 
screened versus the DapE enzyme.  Given the very good 
potency of the ACE inhibitor L-captopril noted above 
(IC50 = 3.3 µM), the ACE inhibitor enalapril was 
 screened, but did not show any potency versus DapE.  
Two simple hydroxamate compounds, acetohydroxamic 
acid and N-(benzyloxycarbonyl)hydroxylamine 
(actually an N-hydroxy carbamate) were also screened 
but were too weak to measure the inhibitory potency.  
N-Phenylthiourea could potentially function as a zinc-
binding compound and showed some inhibition of 
DapE, but the IC50 is greater than 100 µM.  Phosphonic 
acids can also inhibit metalloproteases, and (2-
carboxyethyl)phosphonic acid was shown to have a very 
weak IC50 of 1,620 µM. 
 
Table 3. Other potential inhibitors explored for the DapE enzyme 
Compound Structure IC50 (µM) 
Enalapril 
(maleate salt) 
N
H
N
O CO2H
CO2Et CH3
 
>1000 
Aceto- 
hydroxamic 
acid 
 
>1000 
N-(Benzyloxy-
carbonyl)hydro
xylamine 
 
>1000 
N-phenyl- 
thiourea 
 
> 100 
(2-
carboxyethyl)- 
phosphonic acid 
 
1620 
Ki = 800 µM 
aValues are means of three experiments, standard deviation is given in 
parentheses.  
 
Several alkyl and aryl phosphates have also been tested 
in addition to diaminopimelic acid amides and ornithine 
amides (structures not shown).  In all cases, these 
molecules exhibited little or no inhibitory potency (IC50 
>1000 µM - >10,000 µM).  Finally, (D,L)-(2-
phosphonomethyl)-pentanedioic acid did not inhibit 
DapE at concentrations up to 10 mM.  2-Carboxyethyl 
phosphonic acid is a significantly better inhibitor (Ki = 
800 µM) than phosphonoacetic acid, 3-phospho-
propanoic acid, or N-(phosphonomethyl)glycine, thus 
presenting an optimal chain length for interactions with 
DapE.  We expect an optimal distance between thiol 
and carboxylate in the thiol series as well, depending on 
conformational mobility of the series.   
 
We have confirmed antibiotic activity with the DapE 
inhibitor, L-captopril, in an antibiotic plate assay as 
illustrated in the following photos (Figure 2).  
Application of L-captopril directly to plates cultured 
with E. coli showed a dose-responsive antibiotic activity 
for this DapE inhibitor.  Very little inhibition is 
observed for 1 mg of L-captopril, but 5 mg 
demonstrates a clear positive antibiotic result, and the 
zone of inhibition is even greater for 20 mg of L-
captopril.  Furthermore, this confirms that the enzyme 
inhibitor is crossing the bacterial cell membrane and 
reaching the desired target.  The positive antibiotic 
control ampicillin is shown as well showing its zone of 
inhibition.   
 
   
      1 mg L-captopril        5 mg L-captopril  
  
       20 mg L-captopril          1 mg ampicillin 
Figure 2. Antibiotic Activity of L-Captopril Against E. coli. 
 
In summary, a screen of compounds containing ZBG’s 
against DapE from Haemophilus influenzae has 
delivered a number of micromolar inhibitors including 
captopril, functioning as a competitive, reversible 
inhibitor with an IC50 of 3.3 µM (Ki = 1.8 µM).  
Furthermore, antibiotic activity has now been 
demonstrated for the DapE inhibitor L-captopril.  
Captopril is an excellent lead for medicinal chemistry 
optimization in consideration of its low molecular 
weight (217) and low measured logP of 0.3418,19 
following the rules of Lipinski20 and containing few 
rotatable bonds,21 consistent with its known oral 
bioavailability. 
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